Nathalie Arendt
Doktorand vid Institutionen för medicinsk cellbiologi; Forskargrupp Femke Heindryckx
- E-post:
- nathalie.arendt@mcb.uu.se
- Besöksadress:
- BMC
Husargatan 3
751 23 Uppsala - Postadress:
- Box 571
751 23 UPPSALA
Publikationer
Senaste publikationer
-
Ingår i FEBS Open Bio, 2026
- DOI för Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
- Ladda ner fulltext (pdf) av Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
-
Ingår i Therapeutic Advances in Medical Oncology, 2026
- DOI för Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
- Ladda ner fulltext (pdf) av Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
-
Ingår i Biomedicine and Pharmacotherapy, 2025
- DOI för A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
- Ladda ner fulltext (pdf) av A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
-
Ingår i Therapeutic Advances in Medical Oncology, s. 1-30, 2025
- DOI för Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
- Ladda ner fulltext (pdf) av Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
-
Ingår i European Journal of Pharmacology, 2025
- DOI för Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
- Ladda ner fulltext (pdf) av Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
Alla publikationer
Artiklar i tidskrift
-
Ingår i FEBS Open Bio, 2026
- DOI för Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
- Ladda ner fulltext (pdf) av Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
-
Ingår i Therapeutic Advances in Medical Oncology, 2026
- DOI för Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
- Ladda ner fulltext (pdf) av Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
-
Ingår i Biomedicine and Pharmacotherapy, 2025
- DOI för A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
- Ladda ner fulltext (pdf) av A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
-
Ingår i Therapeutic Advances in Medical Oncology, s. 1-30, 2025
- DOI för Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
- Ladda ner fulltext (pdf) av Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
-
Ingår i European Journal of Pharmacology, 2025
- DOI för Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
- Ladda ner fulltext (pdf) av Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
-
Ingår i European journal of pharmaceutics and biopharmaceutics, 2025
- DOI för A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats
- Ladda ner fulltext (pdf) av A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats